APGE241115C75000
- 0.00
- 0.000.00%
Apogee Therapeutics Newsroom
Apogee Therapeutics to Participate in Upcoming November Investor Conferences
BTIG Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Raises Target Price to $100
TD Cowen Maintains Apogee Therapeutics(APGE.US) With Buy Rating
Apogee Therapeutics Price Target Maintained With a $87.00/Share by Wedbush
Apogee Therapeutics Analyst Ratings
Apogee Therapeutics Unveils Promising Phase 1 Trial Results
Express News | Apogee Therapeutics Announces Results up to 9 Months From Phase 1 Trial of Apg777, Its Novel Half-Life Extended Anti-Il-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases
Apogee Therapeutics Announces Results Up to 9 Months From Phase 1 Trial of APG777, Its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases
Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting
Apogee Therapeutics, Inc. (APGE): A Hot Stock to Buy Now
Wellington Management Group LLP Increases Stake in Apogee Therapeutics Inc
Express News | Wellington Management Group Llp Reports 10.70% Passive Stake in Apogee Therapeutics, Inc. as of Sept 30 - SEC Filing
BTIG Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Maintains Target Price $81
Buy Rating on Apogee Therapeutics' APG808: Market Potential and Treatment Advantages Amid FDA Approval Landscape
Express News | Apogee Therapeutics Inc : Guggenheim Raises Target Price to $95 From $91
Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit
Press Release: Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer
Apogee Therapeutics Insider Sold Shares Worth $1,904,841, According to a Recent SEC Filing
Don't Ignore The Insider Selling In Apogee Therapeutics
Insider Sale: CFO Jane Henderson Sells 6,000 Shares of Apogee Therapeutics Inc (APGE)